Literature DB >> 7964618

Absence of varicella-zoster virus (VZV) glycoprotein V does not alter growth of VZV in vitro or sensitivity to heparin.

J I Cohen1, K E Seidel.   

Abstract

Varicella-zoster virus (VZV) encodes at least five glycoproteins, gpI to gpV. VZV gpV, M(r) 100K to 110K, is the product of VZV open reading frame (ORF) 14. VZV gpV is homologous to herpes simplex virus gC and pseudorabies virus gIII. To determine whether gpV is required for viral replication, we inserted a stop codon after the fifteenth codon of the ORF14 gene in a cosmid containing the gene. Transfection of human melanoma cells with the cosmid containing the mutant ORF14 gene and three other cosmids resulted in the production of infectious VZV. Immunoprecipitation indicated that the mutant virus did not express gpV. VZV that did not express gpV grew at the same rate as parental virus and was inhibited by heparin to a similar extent. The pattern of inhibition by heparin of the gpV mutant was similar to that reported for a herpes simplex virus mutant that does not contain gC, but different from that described for a pseudorabies virus mutant devoid of gIII. These results indicate that VZV gpV is not required for viral replication in vitro.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7964618     DOI: 10.1099/0022-1317-75-11-3087

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  18 in total

Review 1.  Herpesviruses and heparan sulfate: an intimate relationship in aid of viral entry.

Authors:  D Shukla; P G Spear
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

2.  Delayed biosynthesis of varicella-zoster virus glycoprotein C: upregulation by hexamethylene bisacetamide and retinoic acid treatment of infected cells.

Authors:  Johnathan Storlie; Wallen Jackson; Jennifer Hutchinson; Charles Grose
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

3.  Varicella-Zoster Virus Glycoproteins: Entry, Replication, and Pathogenesis.

Authors:  Stefan L Oliver; Edward Yang; Ann M Arvin
Journal:  Curr Clin Microbiol Rep       Date:  2016-09-09

Review 4.  The varicella-zoster virus genome.

Authors:  Jeffrey I Cohen
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

5.  Varicella zoster virus latency.

Authors:  Emily Eshleman; Aamir Shahzad; Randall J Cohrs
Journal:  Future Virol       Date:  2011-03       Impact factor: 1.831

6.  High-level expression of Marek's disease virus glycoprotein C is detrimental to virus growth in vitro.

Authors:  B Karsten Tischer; Daniel Schumacher; Danièlle Chabanne-Vautherot; Vladimir Zelnik; Jean-François Vautherot; Nikolaus Osterrieder
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

7.  The insulin degrading enzyme binding domain of varicella-zoster virus (VZV) glycoprotein E is important for cell-to-cell spread and VZV infectivity, while a glycoprotein I binding domain is essential for infection.

Authors:  Mir A Ali; Qingxue Li; Elizabeth R Fischer; Jeffrey I Cohen
Journal:  Virology       Date:  2009-02-23       Impact factor: 3.616

8.  Discordant varicella-zoster virus glycoprotein C expression and localization between cultured cells and human skin vesicles.

Authors:  Johnathan Storlie; John E Carpenter; Wallen Jackson; Charles Grose
Journal:  Virology       Date:  2008-10-26       Impact factor: 3.616

Review 9.  Protein-glycosaminoglycan interactions: infectiological aspects.

Authors:  D Sawitzky
Journal:  Med Microbiol Immunol       Date:  1996-02       Impact factor: 3.402

10.  Genome-wide mutagenesis reveals that ORF7 is a novel VZV skin-tropic factor.

Authors:  Zhen Zhang; Anca Selariu; Charles Warden; Grace Huang; Ying Huang; Oluleke Zaccheus; Tong Cheng; Ningshao Xia; Hua Zhu
Journal:  PLoS Pathog       Date:  2010-07-01       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.